Public Citizen Urges “Black Box” On Vision Loss For Erectile Dysfunction Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The advocacy group’s petition also asks FDA to require that manufacturers establish a patient registry to track cases of non-arteritic ischemic optic neuropathy.
You may also be interested in...
Pfizer Turns To Lipitor DTC To Pump Up Lipid-Lowering Market
Pfizer hopes new branded and unbranded ads will reinvigorate the cholesterol-lowering category following flat third-quarter sales for the statin in the U.S.
FDA Public Education On ED Drug Vision Risk Is Lacking, Sen. Grassley Says
Senate Finance Committee chair seeks FDA strategy for disseminating drug safety information to patients not requiring physician follow-up.
Erectile Dysfunction Class Labeling Does Not Assert Causal Link To Vision Loss
Labeling revisions for Viagra, Levitra and Cialis will add information about NAION adverse events, but states that “it is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors.”